Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Mallika Singh(Revolution Medicines (United States)), Matthew Holderfield(Revolution Medicines (United States)), Bianca J. Lee(Revolution Medicines (United States)), Jingjing Jiang(Revolution Medicines (United States)), Aidan C.A. Tomlinson(Revolution Medicines (United States)), Kyle J. Seamon(Revolution Medicines (United States)), Alessia Mira, Enricho Patrucco, Grace Goodhart(University of Cincinnati), Julien Dilly(Dana-Farber Cancer Institute), Yevgeniy Gindin(Revolution Medicines (United States)), Nuntana Dinglasan(Revolution Medicines (United States)), Ying Wang(Revolution Medicines (United States)), Lo Lai(Revolution Medicines (United States)), Shurui Cai(Revolution Medicines (United States)), Lingyan Jiang(Revolution Medicines (United States)), Yu Chi Yang(Revolution Medicines (United States)), Nicole Nasholm(Revolution Medicines (United States)), James Evans(Revolution Medicines (United States)), Nilufar Montazer(Revolution Medicines (United States)), Oliver Lai(Revolution Medicines (United States)), Jade Shi(Revolution Medicines (United States)), Ethan Ahler(Revolution Medicines (United States)), Stephanie Chang(Revolution Medicines (United States)), Anthony Salvador(Revolution Medicines (United States)), Abby Marquez(Revolution Medicines (United States)), Jim Cregg(Revolution Medicines (United States)), Yang Liu(Revolution Medicines (United States)), Anthony N. Milin(Revolution Medicines (United States)), Anqi Chen(Revolution Medicines (United States)), Tamar Bar Ziv(Revolution Medicines (United States)), Dylan Parsons(Revolution Medicines (United States)), John E. Knox(Revolution Medicines (United States)), Jennifer A. Roth(Broad Institute), Matthew G. Rees(Broad Institute), Melissa M. Ronan(Broad Institute), Antonio Cuevas-Navarro(Universidad Católica de Santa Fe), Feng Hu(Memorial Sloan Kettering Cancer Center), Piro Lito(Memorial Sloan Kettering Cancer Center), David Santamarı́a(Universidad de Salamanca), Andrew J. Aguirre(Dana-Farber Cancer Institute), Andrew P. Waters(University of Cincinnati), Channing J. Der, Chiara Ambrogio(University of Turin), Zhengping Wang(Revolution Medicines (United States)), Adrian L. Gill(Revolution Medicines (United States)), Elena S. Koltun(Revolution Medicines (United States)), Jacqueline A.M. Smith(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States))
Cited by 5Open Access